ASCP 2017



Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims for improving patient access to medical innovations by working with all relevant stakeholders. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2016 employed more than 94,000 people worldwide. In 2016, Roche invested CHF 9.9 billion in R&D and posted sales of CHF 50.6 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law.

About Roche Diagnostics Middle East

Roche have taken the unprecedented move of being the first IVD company to have a Management Center and a logistics hub in the Middle East. Roche has extended its ownership of the entire supply chain, quality control and customer support all the way into the centre of the region. This base of operations reinforces the commitment to global Roche standards and is driven by a full team of vastly experienced specialists offering a complete portfolio of services. With this regional empowerment, Roche has moved its leadership and decision-making closer to its customers and distributors. These investments allow Roche Diagnostics Middle East to develop from being a supplier into becoming the preferred IVD partner for its customers.
Roche Diagnostics Middle East offers a complete portfolio of services in 16 countries: UAE, Saudi Arabia, Iraq, Iran, Qatar, Kuwait, Bahrain, Oman, Yemen, Syria, Jordan, Palestine, Lebanon, Egypt, Libya and Maldives. For more information, please visit


Cleveland Clinic Abu Dhabi is a unique and unparalleled extension of US-based Cleveland Clinic’s model of care, specifically designed to address a range of complex and critical care requirements unique to the Abu Dhabi population. Cleveland Clinic Abu Dhabi has five Centers of Excellence in the following Institutes: Heart & Vascular, Neurological, Digestive Disease, Eye and Respiratory & Critical Care. Other Institutes include Surgical Subspecialties, Medical Subspecialties, Emergency Medicine, Anesthesiology, Pathology & Laboratory Medicine, Imaging, and Quality & Patient Safety. In all, more than 30 medical and surgical specialties are represented at Cleveland Clinic Abu Dhabi.

The facilities at Cleveland Clinic Abu Dhabi combine state-of-the-art amenities and world-class service standards. The hospital is a 364 (expandable to 490) bed facility, with five clinical floors, three diagnostic and treatment levels, and 13 floors of critical and acute inpatient units. It is a physician-led medical facility served by North American board certified (or equivalent) physicians. Cleveland Clinic Abu Dhabi provides patients in the region direct access to the world’s best healthcare providers and Cleveland Clinic’s unique model of care, reducing their need to travel abroad for treatment.

About Our Partners
Cleveland Clinic Abu Dhabi is the result of an agreement signed in 2006 between Mubadala Development Company (Mubadala), and US-based Cleveland Clinic in support of the Abu Dhabi government’s Economic Vision 2030 to develop a robust, world-class healthcare sector in the Emirate. Their shared vision is to bring the highest international standards of patient care to treat the complex and critical healthcare needs of the Abu Dhabi population. For more information, visit